What Happens With AbbVie If Its Allergan Buyout Is Blocked?
A deal isn't done until the ink dries on the paper. And for AbbVie's (NYSE: ABBV) pending acquisition of Allergan (NYSE: AGN), the ink hasn't dried yet.
AbbVie first announced plans to buy Allergan in June 2019. CEO Rick Gonzalez stated in the company's Q4 conference call earlier this month that the deal was on track to close in the first quarter of 2020.
But now there's a threat that could prevent the transaction from receiving regulatory clearance from the U.S. Federal Trade Commission (FTC). What happens for AbbVie if its Allergan buyout is blocked?
Source Fool.com
